Skip to main content
Tego Science, Inc. logo

Tego Science, Inc. — Investor Relations & Filings

Ticker · 191420 ISIN · KR7191420009 KO Manufacturing
Open in API
Filings indexed 155 across all filing types
Latest filing 2025-03-19 Audit Report / Informat…
Country KR South Korea
Listing KO 191420

About Tego Science, Inc.

http://www.tegoscience.com/

Tego Science, Inc. is a biopharmaceutical company specializing in the development and commercialization of cell therapies for regenerative medicine. The company leverages proprietary, advanced cell culture technology for the mass production of human epithelial cells. Its portfolio of approved products includes Holoderm®, an autologous cultured epidermis for severe burns; Kaloderm®, an allogeneic cell therapy for burns and diabetic foot ulcers; and Rosmir®, an autologous fibroblast treatment for wrinkles. In addition to its therapeutic products, Tego Science provides Neoderm®, a 3D cultured skin model used as an alternative to animal testing, and offers CDMO services. The company's clinical pipeline features TPX-115, a first-in-class allogeneic fibroblast-based therapy for treating rotator cuff tears, currently in late-stage clinical trials.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Tego Science. It contains the auditor's opinion (적정/Unqualified), financial statements (assets, liabilities, equity, profit/loss), and details regarding the audit process. In the context of Korean regulatory filings (DART), this is a standard disclosure of the audit report results, which falls under the 'Audit Report / Information' category. FY 2024
2025-03-19 Korean
사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Tego Science, covering the 24th fiscal year (2024). It contains comprehensive company information, financial data, business operations, and management details, which is the standard format for an Annual Report (10-K equivalent) in the Korean regulatory system (DART). FY 2024
2025-03-19 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting (주주총회소집결의) issued by Tego Science. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements and the re-election of directors. This type of document is a standard proxy solicitation or notice of meeting material provided to shareholders to inform them of the upcoming meeting and the items to be voted upon.
2025-03-06 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Tego Science. It contains the meeting agenda, details on voting procedures (including electronic voting), and management information such as director activities and financial statements (balance sheet, income statement, etc.) for the 24th fiscal year. In the context of corporate filings, a document that serves as the official notice and information package for an upcoming shareholder meeting is classified as a Proxy Solicitation & Information Statement (PSI).
2025-03-06 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with other companies' meetings due to scheduling conflicts. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves, the proxy statement, or the voting results, it falls under the general regulatory filing category.
2025-03-06 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Tego Science. It contains the agenda for the meeting, details on voting procedures (including electronic voting), and management information such as director candidates and financial statements. This type of document is a standard proxy solicitation material sent to shareholders to inform them of the upcoming meeting and request their votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.